These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29786179)

  • 1. [Update 2017 of the KDIGO guidelines on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). What are the real changes?].
    Pasquali M; Bellasi A; Cianciolo G; Massimetti C; Mereu MC; Morrone L; Panuccio V;
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphophonates in CKD patients with low bone mineral density.
    Liu WC; Yen JF; Lang CL; Yan MT; Lu KC
    ScientificWorldJournal; 2013; 2013():837573. PubMed ID: 24501586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Uhlig K; Berns JS; Kestenbaum B; Kumar R; Leonard MB; Martin KJ; Sprague SM; Goldfarb S
    Am J Kidney Dis; 2010 May; 55(5):773-99. PubMed ID: 20363541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Kidney Int; 2017 Jul; 92(1):26-36. PubMed ID: 28646995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.
    Ketteler M; Block GA; Evenepoel P; Fukagawa M; Herzog CA; McCann L; Moe SM; Shroff R; Tonelli MA; Toussaint ND; Vervloet MG; Leonard MB
    Ann Intern Med; 2018 Mar; 168(6):422-430. PubMed ID: 29459980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To what extent can we achieve mineral bone metabolism treatment targets suggested by the KDIGO guidelines among chronic kidney disease stage 3 - 5 non-dialysis patients?
    Dincer MT; Ozcan SG; Alagoz S; Karaca C; Gulcicek SH; Trabulus S; Pekpak M; Seyahi N
    Clin Nephrol; 2022 Nov; 98(5):239-246. PubMed ID: 35979902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder.
    Seng JJB; Tan YLC; Lim RW; Ng HTS; Lee PH; Wong J
    Int Urol Nephrol; 2018 Oct; 50(10):1871-1877. PubMed ID: 29882003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Komaba H; Tanaka M; Fukagawa M
    Intern Med; 2008; 47(11):989-94. PubMed ID: 18520108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults.
    Bellorin-Font E; Ambrosoni P; Carlini RG; Carvalho AB; Correa-Rotter R; Cueto-Manzano A; Jara A; Jorgetti V; Negri AL; Olaizola I; Salusky I; Slatopolsky E; Weisinger JR; ;
    Nefrologia; 2013; 33 Suppl 1():1-28. PubMed ID: 23629678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
    Haffner D; Leifheit-Nestler M
    Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
    Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CKD-MBD: impact on management of kidney disease.
    Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease].
    Ureña-Torres PA; Cozzolino M; Bover J
    Nephrol Ther; 2018 Jun; 14(4):189-200. PubMed ID: 29545131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities.
    Rodzoń-Norwicz M; Norwicz S; Sowa-Kućma M; Gala-Błądzińska A
    Endokrynol Pol; 2023; 74(5):490-498. PubMed ID: 37902013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.